Background: Mitoxantrone is used for aggressive multiple sclerosis (MS), but concerns about safety, including cardiotoxicity and other laboratory measures, prevail.
Mitoxantrone is licensed in the United States and some European countries, and is used "off label" in other countries, including Canada, as a disease-modifying therapy for multiple sclerosis (MS).
Despite its promising therapeutic effects, [1] [2] [3] [4] widespread use of mitoxantrone for MS is hindered by concerns about potential adverse events. Cardiotoxicity is a major concern; mitoxantrone treatment can result in cardiomyopathy leading to reduced left ventricular ejection fraction (LVEF) and irreversible congestive heart failure. 5 Risk increases with cumulative dose, 6, 7 limiting the recommended lifetime dose in MS to 140 mg/m 2 . Other potential adverse events include myelosuppression, leading to anemia, neutropenia or leukopenia, and liver toxicity. 1, 2, 4, [8] [9] [10] [11] The mitoxantrone clinical trials for MS reported low rates of adverse events, whereas some postmarketing studies have revealed a higher incidence of adverse events, particularly subclinical cardiac events. [12] [13] [14] [15] We examined cardiotoxicity and other laboratory adverse events in a cohort of patients with MS treated with mitoxantrone during routine clinical practice. Sex, age, disease duration, and cumulative dose were investigated as possible predictors of adverse events.
METHODS This retrospective review included all patients
with MS treated with mitoxantrone at the University of British Columbia (UBC) MS Clinic, Vancouver, Canada, with first infusion between July 1999 and December 2007. Subsequent treatments and monitoring were followed up to January 2009. Mitoxantrone is used at the UBC MS clinic to treat patients with active and aggressive MS. Contraindications include use of a cardiotoxic or cytotoxic medication, history of heart disease, and pregnancy or breast-feeding.
The standard treatment protocol during the study period consisted of mitoxantrone (12 mg/m 2 IV) infused over 30 minutes, preceded by methylprednisolone (1 g IV) and dolasetron (100 mg IV). Mitoxantrone was administered monthly for 3 months, and then 3-monthly to a maximum cumulative dose of 120 mg/m 2 . Cardiac function was monitored by a cardiologist and included multiple-gated acquisition (MUGA) scans before infusion (baseline), after the third and sixth doses, and then at the physician's discretion. Complete blood cell count and biochemical liver tests were performed before each infusion. Reduction or termination of infusions due to adverse events was at the physician's discretion.
Laboratory indication of mitoxantrone-induced cardiotoxicity (measured by LVEF) was the primary outcome of interest. Myelosuppression, anemia, and liver toxicity, as measured by neutrophil count, hemoglobin level, and increased aspartate aminotransferase (AST), were also investigated. Patients with normal baseline LVEF (Ն50%), neutrophil count (Ն the lower limit of normal [LLN]), hemoglobin level (Ն LLN), or AST (Յ the upper limit of normal [ULN]) and with Ն1 follow-up test result were included in the respective analyses.
Adverse events were described according to the Common Toxicity Criteria for Adverse Events, version 4, as grade 1 (mild), 2 (moderate), 3 (severe), or 4 (life threatening). 16 The influence of sex, age (Յ35, 36 -45, and Ͼ46 years), disease duration (Յ5, 6 -11, and Ն12 years) and cumulative dose of mitoxantrone on the odds of each subclinical adverse event occurring in repeated measures was explored using the generalized estimating equation (GEE). Cardiotoxicity was defined as a follow-up resting LVEF Ͻ50% or an absolute reduction in LVEF Ն10% points from baseline; equivalent to at least a grade 2 adverse event (the lowest grade available for this type of adverse event 16 ). Grade 1 or higher events were used to define neutropenia (neutrophil count Ͻ LLN), anemia (hemoglobin Ͻ LLN), and liver toxicity (AST Ͼ UNL). ULN and LLN values were provided by each testing laboratory. All multivariable models were adjusted for ethnicity (white vs nonwhite) and body mass index (BMI).
Potential bias created by the exclusion of patients from the cardiotoxicity analysis was explored by comparing their characteristics to those of the included patients using the 2 test and the t test. All analyses were performed using SPSS version 15.0 (SPSS Inc., Chicago IL; 2006.).
Standard protocol approvals, registrations, and patient consents. The UBC Clinical Ethics Board approved the study.
Written informed consent was obtained from all patients participating in the study.
RESULTS
During the study period, 163 patients with MS received at least 1 infusion of mitoxantrone; their baseline characteristics and treatment details are shown in table 1. In total, 160 patients were included in at least 1 of the analyses; reasons for exclusion are listed in table 2. Patients excluded from the cardiotoxicity analysis (n ϭ 35) were comparable to those included (n ϭ 128) by sex, age, disease duration, ethnicity, clinical course, and BMI ( p Ͼ 0.05). Excluded patients, however, received a lower cumulative dose of mitoxantrone ( p Ͻ 0.001). All 163 patient files were reviewed for serious adverse events.
Cardiotoxicity. Among 128 patients with normal baseline LVEF, 18 (14%) developed reduced LVEF (grade 2 toxicity) during follow-up. Of these, 3 (17%) recovered to normal at their next assessment, but 9 (50%) had 2 consecutive low MUGA scans. The remaining 6 had no further available follow-up. In GEE analyses, a subclinical reduction in LVEF was not associated with cumulative dose of mitoxantrone, sex, age, or disease duration (figure e-1A on the Neurology ® Web site at www.neurology.org). One woman had nonfatal coronary heart failure 31 months after treatment end (cumulative dose 75.7 mg/m 2 ), having demonstrated a significantly decreased LVEF during monitoring without full recovery.
Neutropenia. Among 146 patients, 40 (27%) had 1 or more follow-up reduced neutrophil counts (grade Ն1); of these, neutropenia was evident in 26 (18% of all patients) outside of the nadir (i.e., excluding measurements taken 10 -18 days after infusion). Seventeen cases had severely decreased counts (grade 3 or 4), but all recovered to at least 1.0 ϫ 10e9/L (grade 2). Neutropenia was not associated with any of the considered variables in GEE analyses (figure e-1B).
Anemia. Low hemoglobin levels developed in 21 of 139 patients (15%). The maximum toxicity reached (2 cases) was grade 2 (Ͻ100 g/L to 80 g/L) after low cumulative doses of mitoxantrone (Ͻ50 mg/m 2 ) and being sustained well after treatment ended. Women had a greater odds of low hemoglobin than men (adjusted odds ratio [OR] 8.61, 95% confidence interval [CI] 2.25-32.85), and among women, anemia was associated with increasing dose of mitoxantrone (adjusted OR 1.26, 95% CI 1.08 -1.48 per 10 mg/ m 2 ; figure e-1C).
Liver toxicity. Increased AST developed in 21 of 134 patients (16%); the maximum toxicity reached was grade 2 (Ͼ3.0 -5.0 ϫ ULN). GEE analyses revealed no significant predictors of increased AST (figure e-1D).
DISCUSSION
The incidence of subclinical cardiotoxicity was higher than that reported in the phase II/III mitoxantrone clinical trials 2,4 and by some, 11, 17, 18 although not all, [12] [13] [14] [15] postmarketing studies.
This adverse event is considered moderate by recognized standard criteria, 16 but the potential longterm consequences are unknown. Interestingly, no dose-response effect was observed, perhaps because of the relatively narrow dose range used in this cohort. This underlines the need for careful monitoring of all patients with MS during and after treatment as emphasized by the recent, more stringent US Food and Drug Administration guidelines. 19 These recommendations include LVEF evaluation before every dose of mitoxantrone and annual evaluations after treatment cessation to detect late-occurring cardiotoxicity.
The observed differences between the results of clinical trials and postmarketing studies are likely due to variation in total follow-up, patient populations, timing of laboratory measurements, monitoring techniques (such as MUGA vs echocardiogram), and criteria for cardiotoxicity. Notably, the definition of decreased LVEF has been inconsistent between studies; greater homogeneity and clarity regarding the criteria used in reports of mitoxantrone-related cardiotoxicity would facilitate pooling and interpretation across studies.
As observed by others, 7, 17 we found no association of cardiac events with sex or age; we also found no association with MS disease duration at start of treatment. None of these indicators can be regarded as helpful prognostic factors for mitoxantrone associated cardiotoxic events.
The incidences of reversible anemia or neutropenia in patients with MS exposed to mitoxantrone were higher than those reported in the pivotal trial, 4 but the incidences of liver toxicity were comparable. These adverse events were mostly transient and not severe. Anemia was far more common in women and was associated with a higher dose; women in particular should be carefully monitored for signs of anemia during mitoxantrone treatment for MS.
Patients with MS could potentially be more susceptible to cardiotoxic or other adverse events; there is evidence that both low ventricular ejection fraction 20 and increased liver enzymes 21 are more fre- quent in "untreated" patients with MS than expected. This emphasizes the need for careful monitoring when exposing patients with MS to potentially toxic treatments. The lack of an untreated comparison group is a limitation of our study; however, serial LVEF measurements would be too invasive to justify enrollment of a control group outside of a clinical trial. Our data were collected retrospectively, and as a result, the documentation was unavoidably incomplete. Excluded patients were exposed to a lower cumulative dose of mitoxantrone and might have experienced more adverse events precipitating cessation of treatment, potentially resulting in an underestimate of the adverse event rate.
These results indicate that cardiotoxic events are evident in patients with MS after doses of mitoxantrone well below current maximum recommended levels. Thus, there is potential for cardiac injury even at the low doses given to patients with MS. Although mitoxantrone was reasonably well tolerated in our cohort over the short term, the long-term cardiac effects are unknown, and extended prospective follow-up is required to examine these and other serious potential side effects of treatment.
